Inhibitors of ABCB1 and ABCG2 overcame resistance to topoisomerase inhibitors in small cell lung cancer

BACKGROUND: Small cell lung cancer (SCLC) is a highly aggressive disease with a poor prognosis. Although most patients initially respond to topoisomerase inhibitors, resistance rapidly emerges. The aim, therefore, is to overcome resistance to topoisomerase I (irinotecan) or II (etoposide) inhibitors...

Descripción completa

Detalles Bibliográficos
Autores principales: Omori, Miwako, Noro, Rintaro, Seike, Masahiro, Matsuda, Kuniko, Hirao, Mariko, Fukuizumi, Aya, Takano, Natsuki, Miyanaga, Akihiko, Gemma, Akihiko
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons Australia, Ltd 2022
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9346178/
https://www.ncbi.nlm.nih.gov/pubmed/35719112
http://dx.doi.org/10.1111/1759-7714.14527

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9346178/
https://www.ncbi.nlm.nih.gov/pubmed/35719112
http://dx.doi.org/10.1111/1759-7714.14527

Ejemplares similares